Background: Chronic hepatitis B and C infections represent major risk factors for the development of hepatocellular carcinoma (HCC). Recently, the management of patients with viral hepatitis has dramatically changed. In the present review we discuss the impact of these developments on the prevention of HCC as well as the treatment of patients with HCC. Methods: Studies indexed in Medline between 1990 and 2015 (November) were reviewed. The terms ‘hepatocellular carcinoma', ‘HCC', ‘hepatitis B', ‘hepatitis C', ‘viral hepatitis', and combinations of these terms were used. Results: Patients with chronic hepatitis B or hepatitis C without HCC should be evaluated for antiviral therapy, since antiviral therapy was suggested to reduce the risk of HCC development. Cirrhotic patients infected with hepatitis B virus (HBV) require antiviral therapy, while cirrhotics infected with hepatitis C virus (HCV) need to be prioritized for therapy with interferon (IFN)-free regimens. Antiviral therapy should be considered in HBV-infected patients with HCC, especially to prevent tumor recurrence after curative-intended therapy or to prevent hepatic decompensation. HCV-infected patients with HCC should be considered in similar intention for IFN-free antiviral therapy, depending on the tumor stage and life expectancy. Conclusion: Patients with viral hepatitis should be considered for antiviral treatment for the prevention of HCC development as well as during HCC treatment.

Keywords:
Hepatocellular carcinoma, HCC, Viral hepatitis, Hepatitis B virus, HBV, Hepatitis C virus, HCV, Treatment
1.
Forner A, Llovet JM, Bruix J: Hepatocellular carcinoma. Lancet 2012;379:1245-1255.
2.
Dyson J, Jaques B, Chattopadyhay D, et al: Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol 2014;60:110-117.
3.
Parkin DM: The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006;118:3030-3044.
4.
Mittal S, El-Serag HB: Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol 2015;47(suppl):S2-6.
5.
Shi J, Zhu L, Liu S, Xie WF: A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China. Br J Cancer 2005;92:607-612.
6.
Donato F, Boffetta P, Puoti M: A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998;75:347-354.
7.
El-Serag HB: Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012;142:1264-1273.e1261.
8.
Fattovich G, Bortolotti F, Donato F: Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008;48:335-352.
9.
Wang CH, Wey KC, Mo LR, Chang KK, Lin RC, Kuo JJ: Current trends and recent advances in diagnosis, therapy, and prevention of hepatocellular carcinoma. Asian Pac J Cancer Prev 2015;16:3595-3604.
10.
Yoshizawa H: Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: projection to other countries in the foreseeable future. Oncology 2002;62(suppl 1):8-17.
11.
Stroffolini T, Andreone P, Andriulli A, et al: Gross pathologic types of hepatocellular carcinoma in Italy. Oncology 1999;56:189-192.
12.
Lok AS, Everhart JE, Wright EC, et al: Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology 2011;140:840-849; quiz e812.
13.
Roderburg C, Gautheron J, Luedde T: TNF-dependent signaling pathways in liver cancer: promising targets for therapeutic strategies? Dig Dis 2012;30:500-507.
14.
Reig M, Darnell A, Forner A, Rimola J, Ayuso C, Bruix J: Systemic therapy for hepatocellular carcinoma: the issue of treatment stage migration and registration of progression using the BCLC-refined RECIST. Semin Liver Dis 2014;34:444-455.
15.
Reig M, Gazzola A, Di Donato R, Bruix J: Systemic treatment. Best Pract Res Clin Gastroenterol 2014;28:921-935.
16.
European Association for the Study of the Liver: EASL recommendations on treatment of hepatitis C 2014. J Hepatol;61:373-395.
17.
European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer: EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-943.
18.
Plentz RR, Malek NP: New insights from the German guideline ‘hepatocellular carcinoma' (article in German). Dtsch Med Wochenschr 2014;139:2529-2531.
19.
Stotz M, Gerger A, Haybaeck J, Kiesslich T, Bullock MD, Pichler M: Molecular targeted therapies in hepatocellular carcinoma: past, present and future. Anticancer Res 2015;35:5737-5744.
20.
Zhu AX, Park JO, Ryoo BY, et al: Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 2015;16:859-870.
21.
European Association for the Study of the Liver: EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-185.
22.
Aghemo A, Lampertico P, Colombo M: Assessing long-term treatment efficacy in chronic hepatitis B and C: between evidence and common sense. J Hepatol 2012;57:1326-1335.
23.
Marcellin P, Gane E, Buti M, et al: Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013;381:468-475.
24.
Lampertico P, Maini M, Papatheodoridis G: Optimal management of hepatitis B virus infection - EASL Special Conference. J Hepatol 2015;63:1238-1253.
25.
Marcellin P, Ahn SH, Ma X, et al: Combination of tenofovir disoproxil fumarate and peginterferon alfa-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B. Gastroenterology 2016;150:134-144.e10.
26.
Buti M, Tsai N, Petersen J, et al: Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci 2015;60:1457-1464.
27.
Wong GL, Tse YK, Wong VW, Yip TC, Tsoi KK, Chan HL: Long-term safety of oral nucleos(t)ide analogs for patients with chronic hepatitis B: a cohort study of 53,500 subjects. Hepatology 2015;62:684-693.
28.
Lampertico P, Invernizzi F, Vigano M, et al: The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: a 12-year prospective cohort study. J Hepatol 2015;63:1118-1125.
29.
Papatheodoridis GV, Chan HL, Hansen BE, Janssen HL, Lampertico P: Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. J Hepatol 2015;62:956-967.
30.
Papatheodoridis GV, Dalekos GN, Yurdaydin C, et al: Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. J Hepatol 2015;62:363-370.
31.
European Association for the Study of the Liver: EASL recommendations on treatment of hepatitis C 2015. J Hepatol 2015;63:199-236.
32.
Lawitz E, Gane E, Pearlman B, et al: Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2015;385:1075-1086.
33.
Zeuzem S, Ghalib R, Reddy KR, et al: Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med 2015;163:1-13.
34.
Roth D, Nelson DR, Bruchfeld A, et al: Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet 2015;386:1537-1545.
35.
Feld JJ, Jacobson IM, Hezode C, et al: Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 2015;373:2599-2607.
36.
Foster GR, Afdhal N, Roberts SK, et al: Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 2015;373:2608-2617.
37.
Curry MP, O'Leary JG, Bzowej N, et al: Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 2015;373:2618-2628.
38.
Sarrazin C, Berg T, Buggisch P, et al: S3 guideline hepatitis C addendum (article in German). Z Gastroenterol 2015;53:320-334.
39.
van der Meer AJ, Veldt BJ, Feld JJ, et al: Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308:2584-2593.
40.
van der Meer AJ, Wedemeyer H, Feld JJ, Dufour JF, Zeuzem S, Hansen BE, Janssen HL: Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population. JAMA 2014;312:1927-1928.
41.
Charlton M, Everson GT, Flamm SL, et al: Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015;149:649-659.
42.
Papatheodoridis GV, Manolakopoulos S, Touloumi G, et al: Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort. J Viral Hepat 2015;22:120-127.
43.
Zoutendijk R, Reijnders JG, Brown A, et al: Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naive patients with a partial virological response. Hepatology 2011;54:443-451.
44.
Hosaka T, Suzuki F, Kobayashi M, et al: Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013;58:98-107.
45.
Nassal M: HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut 2015;64:1972-1984.
46.
Noordeen F: Hepatitis B virus infection: an insight into infection outcomes and recent treatment options. Virusdisease 2015;26:1-8.
47.
Bruix J, Takayama T, Mazzaferro V, et al: Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 2015;16:1344-1354.
48.
Tabor E: Hepatocellular carcinoma: global epidemiology. Dig Liver Dis 2001;33:115-117.
49.
Pawlotsky JM, Feld JJ, Zeuzem S, Hoofnagle JH: From non-A, non-B hepatitis to hepatitis C virus cure. J Hepatol 2015;62:S87-99.
© 2016 S. Karger GmbH, Freiburg
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.